Form 8-K

0001171843-23-004946.txt : 20230803 0001171843-23-004946.hdr.sgml : 20230803 20230803080024 ACCESSION NUMBER: 0001171843-23-004946 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230803 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230803 DATE AS OF CHANGE: 20230803 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Compass Therapeutics, Inc. CENTRAL INDEX KEY: 0001738021 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39696 FILM NUMBER: 231138145 BUSINESS ADDRESS: STREET 1: 80 GUEST STREET CITY: BOSTON STATE: MA ZIP: 02135 BUSINESS PHONE: 617-500-8099 MAIL ADDRESS: STREET 1: 80 GUEST STREET CITY: BOSTON STATE: MA ZIP: 02135 FORMER COMPANY: FORMER CONFORMED NAME: Olivia Ventures, Inc. DATE OF NAME CHANGE: 20180419 8-K 1 f8k_080223.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 3, 2023

_______________________________

Compass Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Delaware	001-39696	82-4876496
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

80 Guest Street, Suite 601

Boston, Massachusetts 02135

(Address of Principal Executive Offices) (Zip Code)

(617) 500-8099

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	CMPX	NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 3, 2023, Compass Therapeutics, Inc. issued a press release announcing financial results for the second quarter ended June 30, 2023. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Exhibit

99.1		Press Release dated August 3, 2023 (furnished pursuant to Item 2.02)
104		The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Compass Therapeutics, Inc.


Date: August 3, 2023	By:	/s/ Neil Lerner
		Neil Lerner
		VP Finance

EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling

EXHIBIT 99.1

Compass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Continuing to enroll patients in a U.S. Phase 2 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced colorectal cancer (CRC); initial data from this study is expected in the second half of 2023
Opened 20 clinical sites and continues to enroll patients in a U.S. Phase 2 study of CTX-009 in patients with advanced biliary tract cancers (BTC); top line data from this study is now expected in the second half of 2024
Completed enrollment of the dose-escalation portion of the Phase 1 combination arm of CTX-471 (CD137 agonistic antibody) and KEYTRUDA® (pembrolizumab)
Added to the Russell 2000^®and Russell 3000^® Indexes as part of the Russell indexes annual reconstitution
Ended the second quarter with $169 million in cash and marketable securities, providing cash runway for the company into 2026

BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported second quarter, and year-to-date, 2023 financial results.

“Enrollment of our Phase 2 study of CTX-009 in patients with advanced CRC is on track and we expect to report initial data from this study in the second half of this year. Enrollment in our Phase 2 study in patients with BTC has been slower than anticipated, but we have taken steps to address this, including opening of a number of key clinical sites, strengthening our clinical operations team, and increasing our collaboration with patient advocacy groups,” said Thomas J. Schuetz, MD, PhD, Co-Founder and Chief Executive Officer.

“While we continue to advance CTX-009 and CTX-471 in the clinic, we are also gearing toward the filing of our third U.S. IND application, which will be for our next generation bispecific checkpoint axis blocker, CTX-8371. We believe that CTX-8371’s unique mechanism-of-action is the reason for its differentiated activity in pre-clinical studies, and we look forward to advancing it to a first-in-human clinical study,” said Vered Bisker-Leib, PhD, President and Chief Operating Officer.

Development Pipeline Update and Highlights:

CTX-009 (DLL4 and VEGF-A bispecific antibody)

Enrolling patients in the U.S. Phase 2 study of CTX-009 as a monotherapy in patients with advanced, metastatic colorectal cancer
- The study design is an Adaptive Simon Two-Stage, with Stage 1 of the study enrolling 37 patients; if 3 or more responses are confirmed in Stage 1, the study will advance to Stage 2, and an additional 47 patients will be enrolled
- The study is enrolling patients with CRC who have received two or three prior systemic therapies irrespective of their KRAS mutation status
- Patients are being evaluated for safety and tolerability, as well as clinical response
- Initial results from Stage 1 of this study are expected in the second half of 2023
Enrolling patients in the U.S. Phase 2/3 study of CTX-009 in combination with Paclitaxel in BTC
- This randomized Phase 2/3 study is designed to enroll 150 patients with BTC who have received one prior systemic therapy
- The primary endpoint of the study is overall response rate (ORR), and secondary endpoints include progression free survival (PFS), overall survival (OS), clinical benefit rate (CBR) and duration of response (DOR)
- Enrollment for this study has been slower than anticipated; based on our current enrollment estimate, we expect top line data from this study in the second half of 2024

CTX-471 (CD137 + PD-1)

Advancing enrollment of the Phase 1 combination arm of CTX-471 (CD137 agonistic antibody) and Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with select solid tumors
The dose-escalation portion of the study (n=9) has been fully enrolled

Initial results from the combination arm are expected in the second half of 2023

CTX-8371 (PD-1 x PD-L1)

CTX-8371 is a next generation bispecific checkpoint inhibitor that simultaneously targets PD-1 and PD-L1 and exhibits a unique mechanism-of-action that involves cleavage of cell surface PD-1
Targeting IND submission in the third quarter of 2023 and initiating a Phase 1 clinical trial in the fourth quarter of 2023

Financial Results

Net loss for the second quarter ended June 30, 2023 was $11.3 million or $0.09 per common share, compared to $8.5 million or $0.08 per common share for the same period in 2022. Net loss for the six months ended June 30, 2022 was $19.1 million or $0.15 per common share, compared to $15.7 million or $0.16 per common share for the same period in 2022.

Cash Position

As of June 30, 2023, cash and marketable securities were $169 million as compared to $187 million as of December 31, 2022, providing the Company with an anticipated cash runway into 2026. During the first half of 2023, the Company used $22 million of cash to fund operations.

Research and development (R&D) Expenses

R&D expenses were $10.2 million for the quarter ended June 30, 2023, as compared to $5.9 million for the same period in 2022, an increase of approximately $4.4 million or 74%. The change for the quarter was primarily attributable to a net increase of $4.6 million in program costs, resulting primarily from $5.9 million additional spending related to CTX-009 clinical and manufacturing costs offset by a $1.3 million decrease in spending on other programs.

R&D expenses were $16.9 million for the six months ended June 30, 2023, as compared to $10.3 million for the same period in 2022, an increase of $6.6 million or 64%. The change for the year was primarily attributable to a net increase of $7.1 million in program costs, resulting primarily from $9.3 million additional spending related to CTX-009 clinical and manufacturing costs offset by a $2.2 million decrease in spending on other programs.

General and Administrative (G&A) Expenses

G&A expenses were $3.1 million for the quarter ended June 30, 2023 and 2022. G&A expenses were $6.2 million for the six months ended June 30, 2023, as compared to $5.9 million for the same period in 2022, an increase of $0.3 million or 5%.

Upcoming Investor Conferences

Compass management will participate in four upcoming investor conferences:

Wedbush Securities Healthcare Conference
Date: August 8-9, 2023
Location: New York, NY

Citi BioPharma Conference
Date: September 6-7, 2023
Location: Boston, MA

HC Wainwright Global Investment Conference
Date: September 11-13, 2023
Location: New York, NY

Cantor Healthcare Conference
Date: September 26-28, 2023
Location: New York, NY

Live webcasts presentations, when available, will be under “News & Events” in the Investors section of the Company’s website located at www.compasstherapeutics.com.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

About Compass Therapeutics

Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to Compass’s financial position to continue advancing its product candidates, expectations about cash runway, business and development plans, and statements regarding Compass’s product candidates, their development, regulatory plans with respect thereto and therapeutic potential thereof. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, Compass’s ability to raise the additional funding it will need to continue to pursue its business and product development plans, the inherent uncertainties associated with developing product candidates and operating as a development stage company, Compass’s ability to identify additional product candidates for development, Compass’s ability to develop, complete clinical trials for, obtain approvals for and commercialize any of its product candidates, competition in the industry in which Compass operates and market conditions. These forward-looking statements are made as of the date of this press release, and Compass assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents Compass files with the SEC available at www.sec.gov, including without limitation Compass’s latest Form 10-Q and subsequent filings with the SEC.

Investor Contact
ir@compasstherapeutics.com

Media Contact
Anna Gifford, Communications Manager
media@compasstherapeutics.com
617-500-8099


Compass Therapeutics, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(In thousands, except par value)

	June 30, 2023		December 31, 2022
	(unaudited)
Assets
Current assets:
Cash and cash equivalents	$	19,278	$	34,946
Marketable securities		149,474		151,663
Prepaid expenses and other current assets		6,520		8,182
Total current assets		175,272		194,791
Property and equipment, net		1,204		1,567
Operating lease, right-of-use ("ROU") asset		2,385		2,967
Other assets		320		320
Total assets	$	179,181	$	199,645
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$	724	$	3,382
Accrued expenses		7,827		11,690
Operating lease obligations, current portion		1,147		1,097
Total current liabilities		9,698		16,169
Operating lease obligations, long-term portion		1,197		1,838
Total liabilities		10,895		18,007
Total stockholders' equity		168,286		181,638
Total liabilities and stockholders' equity	$	179,181	$	199,645

Compass Therapeutics, Inc. and Subsidiaries
Condensed Consolidated Statement of Operations (unaudited)
(In thousands, except per share data)

	Three Months Ended June 30,						Six Months Ended June 30,
		2023			2022			2023			2022

Operating expenses:
Research and development	$	10,223		$	5,862		$	16,862		$	10,278
General and administrative		3,114			3,125			6,183			5,891
Total operating expenses		13,337			8,987			23,045			16,169
Loss from operations		(13,337	)		(8,987	)		(23,045	)		(16,169	)
Other income		2,059			493			3,930			513
Net loss	$	(11,278	)	$	(8,494	)	$	(19,115	)	$	(15,656	)
Net loss per share - basic and diluted	$	(0.09	)	$	(0.08	)	$	(0.15	)	$	(0.16	)

EX-101.SCH 3 gnw-20190101.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 gnw-20190101_def.xml XBRL DEFINITION FILE EX-101.LAB 5 gnw-20190101_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 gnw-20190101_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT

Cover	Aug. 03, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Aug. 03, 2023
Entity File Number	001-39696
Entity Registrant Name	Compass Therapeutics, Inc.
Entity Central Index Key	0001738021
Entity Tax Identification Number	82-4876496
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	80 Guest Street, Suite 601
Entity Address, City or Town	Boston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02135
City Area Code	617
Local Phone Number	500-8099
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	CMPX
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false

XML 8 f8k_080223_htm.xml IDEA: XBRL DOCUMENT 0001738021 2023-08-03 2023-08-03 iso4217:USD shares iso4217:USD shares 0001738021 false 8-K 2023-08-03 Compass Therapeutics, Inc. DE 001-39696 82-4876496 80 Guest Street, Suite 601 Boston MA 02135 617 500-8099 false false false false Common Stock, $0.0001 par value per share CMPX NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_080223.htm exh_991.htm gnw-20190101.xsd gnw-20190101_def.xml gnw-20190101_lab.xml gnw-20190101_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f8k_080223.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 1, "dts": { "definitionLink": { "local": [ "gnw-20190101_def.xml" ] }, "inline": { "local": [ "f8k_080223.htm" ] }, "labelLink": { "local": [ "gnw-20190101_lab.xml" ] }, "presentationLink": { "local": [ "gnw-20190101_pre.xml" ] }, "schema": { "local": [ "gnw-20190101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "gnw", "nsuri": "http://globenewswire.com/20190101", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_080223.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://globenewswire.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_080223.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001171843-23-004946-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-23-004946-xbrl.zip M4$L#!!0 ( Q U>LKUSE6!< .:U + 97AH7SDY,2YH=&WM77]; MXLBR_@3W._1QY^S5YP8D@/Q0Q^JWJKNX/$_SBY;MW]>G9/?;K]=D*L?GRZ^MLA. M87__9Z6UOW]V>Z8_J!9+Y#:@GN0A%QYU]O?/O^^<'/="UR$.];H?=YA7^'&# M;S%JGQR'/'38R;G=I<%G[G"O>[ROWSIV64B));R0>>''G9#=A_LXRA&Q>C20 M+/PXX)XM!K)@E@_*.R2^P:,N^[CSY?S[^?7I[>7USG"$;S=*P$:Q5"K6:R6S M:#9*S2K>N*]%:0O[@;2[EG!$\''GEX[Z#P3UB0P?'*9E*%"'=[U#$O!N+SR" M3V48"*][]Z?<;H%(+,#[.R!?<@6^+DC^-SLD M9M7/#M\2KD^E)+<]%E"?12&W)+EFO@A"26X8+-(F_XYH (.2NDI$#5U&XY"H0?6XS25HB@'MIR,@/WX8?&9%1B+DD3^_(KU;]_"]R'#DD M?/#A;IM+"RYW>#*<2X,N]PIM$8;"/33+:J4MF)9[$2" A((P+Q".0WP:%0UL<[SO\T>5?^LR#4/L]-=?S'KUB.SZS&V# M$/SOR*7MO;GD/[5MD!WL@Q)=1U(R,%*Y5"H=R\@_B0<&7X%?<,;DBDK^"GT! M^>K9[!Z-+\%P0:J'Y":>?.QY$0 E0)7#JL((ESZ7M.>>DG9HK[_BX*'@\<&L M-8G+'0 ,8#[0 >:EK"_<@Y(>38/_ET>7-[^=T@IU&W2$BI8N@(1G:_7%Q^.B?? MSW_>_/QZ?;Y'"@4R*0X:H"ZK2':_4VG3OPY)Z]O5'WL&.$7B2049TBXSB/#0 MS;L/A8ZP(JG0+WQ()BZUU$CH_+&L-NLS1_BX)%B<'W!8-;A)@II"FTJMOV$T M1M,'C(;$A7#+ #F*&P02V!BMIP=U[SAE+P Z-!(10%C,FQ M'CII) ]T)"\>MP,=997Z?OVE42Z7CLYS7B.BX#GA &(>^C58'0/"G1)IP&(? MQQ5JX1^)BA,#@;H EU[3/2$CO\-*0^5()8<#XEA,IN J(NNIG!^#B16X;!H;7 M=^QA) P;,%; O"XL3-\ 0J=7P"B!BCHP :.NMB1, FB0Z<6P8MH6^CJ]JGB- MJ'UA4>N!= ,1^=)0!C6/B*3Y'<6+V(A7\;Y-N9 0J#_[5$X;.( MP),#-6.KQUF'G-^#8X8<='#9@>S'@N(H4G[V.(!SP-*THC6D()!B1 T8!\_8 MH'J]!MY) _CG2$&Z8%"=L@$^KX#.D,EP$ ] M;O5 %Q#1VDR%"[S# [(!XWJQ3K.9W.HQZ\X7')5V#W!J.\*Z0]=!21N5NEDD M/QF,Y7"&&.B!,R:?X-K-^I$DDYP$*V81,.H&JY<"1R' M!S(L0&S6@2(WTD,>!O\!"6SRB4M8;N&"\78,@2N -1 Z5$B*@$L-1YAH# $) M9SO3X4VYX!7WF$PC,Z)ROL3W 93ZDK(&,098 MVXX+.5*M9S6F?58+Q&P@+[72T5S,8Z@.9,_CYE2KQSPTZ D=R\$ #!0%3C00 M1'&*@#'P/0ZOY0/$>!

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